Glenmark Pharmaceuticals views Romania as the most dynamic market in the region

Glenmark Paharmaceuticals ranks Romania first in the CEE with reference to the dynamic of its business. Poland, Czech Republic and Slovakia were also mentioned in the company’s analysis.

Glenmark started operations on the Romanian market in 2008, providing pharmaceutical products for the cardiovascular segment, and since than has reached the 41st position on the pharmaceuticals market, ranking 15th on the generic pharmaceuticals segment. In the last two years, the company doubled its sales. It holds a 1.5 percent market share in the cardiovascular area.  

The company aims in the following three years to break into the TOP 30 pharma companies in Romania, and is also looking to increase sales by 25 throughout the next fiscal years.

“By the first quarter of 2012, the company will launch 6 new products in the following therapeutical lines: central nervous system, respiratory system, cardiology, and we are also rolling in oncology. Another 18 new products will be launched by 2013, adding to the current 17 products we have in our portfolio”, stated Mariana Wencz, general director of Glenmark Pharmaceuticals Romania.   

Glenmark Pharmaceuticals Ltd (GPL) is an Indian pharmaceuticals company founded in 1977. The company addresses the generic pharmaceuticals segment in emerging markets. GPL, together with its subsidiaries, owns 12 manufacturing facilities in 4 countries and 5 R&D centers.   

Read more about

Israelis and Romanians generated 44% of the revenues registered by Hotel Cișmigiu in H1 2024

read more

Ovidiu Posirca